查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1870370

囊肿纤维化治疗设备市场按产品类型、通路、最终用户、治疗方式、组件和患者类型划分－2025年至2032年全球预测

Cystic Fibrosis Devices Market by Product Type, Distribution Channel, End User, Modality, Component, Patient Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，囊肿纤维化治疗设备市场将成长至 76.3 亿美元，复合年增长率为 11.47%。

关键市场统计数据
基准年 2024 32亿美元
预计年份：2025年 35.7亿美元
预测年份 2032 76.3亿美元
复合年增长率 (%) 11.47%

一个权威的囊肿纤维化医疗器材生态系统框架，它将临床需求、技术进步和交付模式联繫起来，从而推动长期照护效果的实现。

囊肿纤维化仍然是一种复杂的多系统疾病，需要采用综合方法进行呼吸照护、诊断和长期治疗管理。儘管分子疗法的进步已经改变了许多患者的临床病程，但有效的基于器械的肺部药物输送、气道清除、监测和支持治疗策略对于持续降低发病率仍然至关重要。这些器械涵盖了从优化临床决策的诊断平台到优化药物沉积、提高依从性和患者舒适度的治疗输送系统。随着治疗模式从间歇性住院治疗转向持续性家庭管理，器械设计、连接性和使用者体验正成为创新的前沿领域。

肺部输送技术、感测技术、数位整合以及医疗服务分散化等领域的突破性进展如何融合，正在重塑医疗设备的优先事项和临床路径

肺部给药科学、数位医疗和医疗服务模式的进步融合，正推动囊肿纤维化治疗设备领域发生变革性转变。吸入技术的创新使得药物能够有效到达远端气道，而新型雾化器设计和干粉吸入系统则减轻了患者的负担，提高了治疗依从性。同时，小型化感测器和嵌入式分析技术正将以往被动的设备转变为主动数据来源，为个人化治疗方案调整和远端监测策略奠定基础。这些技术变革，加上更广泛的去中心化医疗趋势——例如家庭治疗、远端追踪和专科药房配药——正在减少对急诊机构的依赖，并重新定义临床医生监督与患者自主权之间的关係。

评估2025年美国关税的影响：重塑医疗设备价值链的采购、製造地和商业策略

自2025年起生效的美国新关税，为囊肿纤维化治疗设备的生产和分销所依赖的全球供应链带来了新的复杂性。某些零件和成品进口关税的提高，导致依赖专用泵浦、精密感测器和客製化阀门的医疗设备到岸成本上升。为此，原始设备製造商 (OEM) 和契约製造製造商正在加快关键製造流程的本地化、供应商多元化以及产品重新设计，以在保持临床可靠性的同时降低零件的复杂性。这些调整旨在缓解短期利润压力，同时确保符合监管要求并保障患者照护的连续性。

将产品类型、分销管道、最终用户、治疗方式、组件和患者群体与策略设计和商业化选择联繫起来的详细細項分析

深入了解市场区隔动态对于优化囊肿纤维化医疗器材产品线的产品设计、临床证据和上市策略至关重要。依产品类型分析可发现，市场细分为支持临床决策的诊断平台和实现肺部给药的肺部给药系统。肺部给药系统内部又细分为多种给药方式，包括干粉吸入器、吸入器和雾化器，每种方式在剂量稳定性、维持治疗负担和易用性方面各有优劣，以满足不同肺功能患者的需求。吸入器可进一步分为定量喷雾吸入器和缓雾吸入器。定量吸入器体积小巧，使用方便，而缓雾吸入器则能释放温和的气溶胶，对特定患者族群有益。雾化器技术涵盖多种结构，其中喷射式雾化器因其成熟的临床亲和性而仍被广泛使用。筛孔式喷雾器具有便携性和高效性，超音波雾化器具有高功率，适用于特定的治疗环境。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和战略影响将塑造监管、商业和营运选择。

区域趋势对囊肿纤维化医疗器材的监管路径、报销架构和实施实践有显着影响。在美洲，临床专家中心和成熟的专科药房网路支援新型给药平台的快速推广，而支付方的尽职调查和采购流程则要求提供强有力的卫生经济学证据和清晰的实际疗效证明。随着企业应对关税衝击并寻求缩短前置作业时间，跨境生产能力和近岸外包在美洲地区日益凸显。

策略行动和能力投资能够使领先的医疗设备製造商脱颖而出，并在囊肿纤维化治疗领域创造可持续的竞争优势。

囊肿纤维化医疗器材领域的主要企业正着力于几项策略要务，这些要务将决定最终的赢家。首先，优先开发将精准肺部给药与嵌入式感测和连接功能相结合的整合解决方案的公司，正在创造更永续的价值提案，因为临床医生和支付方越来越期望医疗器材能够产生可操作的数据，以帮助监测患者的依从性和治疗效果。其次，采用模组化设计和灵活製造的製造商在供应不确定时期能够获得韧性优势，能够快速应对零件短缺、关税变化和当地市场需求。

医疗设备製造商和医疗保健领导者应专注于切实可行的策略事项，以确保在囊肿纤维化治疗中实现稳健的采购、快速推广和可衡量的临床价值。

行业领导者应采取一系列有针对性、可操作的优先事项，将技术潜力转化为持续的临床和商业性成功。首先，推广模组化和零件通用的设备设计，以便在不影响临床性能的前提下，实现供应商的快速更换和区域生产转移。这种方法可以降低关税引起的成本波动风险，并缩短供应商和医疗机构的补货前置作业时间。其次，整合能够产生具有临床意义的指标的感测和连接功能，并使这些指标与支付方的证据要求保持一致。这将为基于以患者为中心的治疗结果（而不仅仅是设备功能）的报销谈判奠定基础。

严谨的混合方法研究框架结合了对临床医生和供应链相关人员的访谈、系统性的文献综述和检验，确保了研究结果的实用性和实证性。

本研究采用混合方法，将初步质性研究结果与严谨的二次研究结果进行三角验证，以全面了解囊肿纤维化医疗器材市场。初步研究包括对呼吸系统科医生、呼吸治疗师、采购负责人、专科药剂师和医疗设备工程师进行结构化访谈，以了解实际环境中的需求、采购限制和技术权衡。此外，也透过实地考察和在临床及居家照护环境中进行观察性研究，检验可用性假设并了解工作流程整合的挑战。

策略性结论强调，模组化设计、互联互通、证据产生和适应性商业模式将决定囊肿纤维化设备的成功与否。

总之，囊肿纤维化医疗器材产业正处于一个转折点，技术创新、医疗服务模式的变革以及政策压力的演变在此交汇融合。成功的医疗器材不仅能够输送药物或测量生理指标，更将融入医疗保健流程，成为提高病患依从性、监测病情和支持临床决策的可靠工具。价格波动、区域监管差异以及支付方期望的不断提高等多重压力，使得敏捷性、循证实践和以患者为中心的设计成为永续策略的基石。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 采用智慧雾化器技术，实现即时使用追踪与患者依从性分析
  • 开发携带式高频胸壁振动装置，以增强家庭气道清除疗法
  • 医疗器材製造商与基因疗法开发商合作，整合标靶CFTR递送系统
  • 透过改良干粉吸入器製剂技术和新型间隔器设计，优化CFTR调变器的沉积。
  • 推出一款支援远端医疗的呼吸物理治疗平台，该平台整合了一个可穿戴式咳嗽监测感测器。
  • 实施以患者为中心的设计改进措施，重点在于缩短治疗时间和提高使用者舒适度。
  • 透过监管协调和报销策略，加速创新型囊性纤维化吸入器设备的市场进入。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章囊肿纤维化治疗设备市场（依产品类型划分）

  • 诊断
  • 肺部给药
    • 干粉吸入器
    • 吸入器
      • 定量吸入器
      • 缓雾吸入器
    • 喷雾器
      • 喷射式雾化器
      • 网状雾化器
      • 超音波雾化器

第九章囊肿纤维化治疗设备市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房
  • 专业中心

第十章囊肿纤维化治疗设备市场（依最终用户划分）

  • 诊所
  • 居家照护
  • 医院

第十一章囊肿纤维化治疗设备市场（依治疗方式划分）

  • 侵入性
  • 非侵入性

第十二章囊肿纤维化治疗设备市场（依组件划分）

  • 泵浦
    • 蠕动帮浦
    • 注射式帮浦
  • 感应器
    • 流量感测器
    • 压力感测器
  • 阀门

第十三章 依病患类型囊肿纤维化治疗设备市场

  • 成人版
  • 孩子们

第十四章 各地区囊肿纤维化治疗设备市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章囊肿纤维化治疗设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国囊肿纤维化治疗设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Koninklijke Philips NV
    • Baxter International Inc.
    • Drive DeVilbiss Healthcare, Inc.
    • PARI GmbH
    • Vyaire Medical, Inc.
    • Smiths Group plc
    • Teleflex Incorporated
    • Omron Corporation
    • ResMed Inc.
    • Fisher & Paykel Healthcare Corporation Limited
Product Code: MRR-1A1A064C001D

The Cystic Fibrosis Devices Market is projected to grow by USD 7.63 billion at a CAGR of 11.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.20 billion
Estimated Year [2025] USD 3.57 billion
Forecast Year [2032] USD 7.63 billion
CAGR (%) 11.47%

An authoritative framing of the cystic fibrosis device ecosystem that connects clinical needs, technological advances, and delivery models driving long-term care outcomes

Cystic fibrosis remains a complex, multisystem disease that requires an integrated approach to respiratory care, diagnostics, and long-term therapy management. Advances in molecular therapeutics have changed the clinical course for many patients, yet durable morbidity reduction continues to rely on effective device-based strategies for pulmonary delivery, airway clearance, monitoring, and supportive care. The device landscape spans diagnostic platforms that refine clinical decision making and therapeutic delivery systems designed to optimize deposition, dosing adherence, and patient comfort. As treatment paradigms shift from episodic hospital care to continuous home-based management, device design, connectivity, and user experience have risen to the forefront of innovation.

Against this backdrop, manufacturers and health systems must navigate a confluence of technological innovation, evolving reimbursement models, and tightening regulatory expectations. The interplay between product usability, clinical outcomes, and supply-chain resilience now determines adoption velocity more than ever before. Consequently, stakeholders are evaluating devices not just as hardware, but as integrated care enablers that link diagnostics, inhaled therapies, monitoring sensors, and data analytics to deliver measurable patient benefit. This introduction frames the critical domains that follow, emphasizing the strategic implications for developers, payers, and providers in an era where device performance, patient-centric design, and system-level integration decide clinical and commercial success.

How converging breakthroughs in pulmonary delivery, sensing, digital integration, and care decentralization are reshaping device priorities and clinical pathways

The cystic fibrosis device landscape is undergoing transformative shifts driven by converging advances in pulmonary delivery science, digital health, and care delivery models. Innovations in inhalation technology are enabling more efficient targeting of distal airways, while novel nebulizer designs and dry powder systems are reducing patient burden and improving adherence. Concurrently, sensor miniaturization and embedded analytics are turning traditionally passive devices into active data sources that inform personalized treatment adjustments and remote monitoring strategies. These technological transitions are complemented by a broader move toward decentralizing care: home-based therapies, virtual follow-up, and specialty pharmacy fulfillment are reducing the dependence on acute care settings and redefining the relationship between clinician oversight and patient autonomy.

Regulatory and reimbursement landscapes are also evolving to reflect the clinical value of integrated device-diagnostic solutions, which in turn stimulates investment in combination products and interoperable platforms. Additionally, supply-chain optimization and component-level sourcing decisions are reshaping manufacturing footprints, prompting companies to reconsider vertical integration and design for manufacturability. As stakeholders respond to these shifts, strategic priorities are emerging around human factors engineering, interoperability standards, and evidence generation that ties device use to meaningful clinical endpoints. Ultimately, this confluence of engineering advances, care model innovation, and policy movement is creating a market environment where agility, cross-disciplinary collaboration, and robust clinical validation are the most reliable predictors of sustained adoption.

Assessment of the 2025 United States tariff impacts that have reshaped component sourcing, manufacturing footprints, and commercial strategies across the device value chain

The imposition of new United States tariff measures in 2025 has introduced a new layer of complexity into the global supply chains that underpin cystic fibrosis device manufacturing and distribution. Increased import duties on select components and finished goods have translated into higher landed costs for devices that rely on specialized pumps, precision sensors, and custom valves. In response, OEMs and contract manufacturers have accelerated efforts to localize critical manufacturing steps, diversify supplier bases, and redesign products for reduced parts complexity where clinical fidelity can be preserved. These adjustments aim to mitigate near-term margin pressure while maintaining regulatory compliance and continuity of care for patients.

Downstream effects on distributors and payers are also material. Hospital procurement teams and specialty pharmacies face tighter negotiations as suppliers pass through cost increases, which may influence purchasing cycles and inventory strategies. Meanwhile, manufacturers are reassessing pricing models and commercial terms to protect access without undermining investment in R&D. The tariffs have also highlighted the strategic value of modular device architectures that permit regional sourcing of subassemblies, enabling companies to shift production in response to tariff schedules with less disruption.

Crucially, the tariff landscape has implications beyond cost. It has spurred renewed attention to supply-chain visibility, contract flexibility, and contingency planning. Companies investing in dual-sourcing strategies and strategic stocking arrangements are better positioned to preserve clinical supply continuity and maintain customer trust. At the same time, the policy-induced cost pressure is encouraging collaboration between industry and payers to demonstrate the downstream economic value of devices through reduced hospitalizations and improved long-term outcomes. In sum, tariffs are accelerating structural changes in how devices are designed, sourced, and commercialized, with lasting implications for competitiveness and patient access.

In-depth segmentation analysis connecting product types, distribution channels, end users, modalities, components, and patient cohorts to strategic design and commercialization choices

A granular understanding of segmentation dynamics is essential for tailoring product design, clinical evidence, and go-to-market approaches across the cystic fibrosis device continuum. When analyzed by product type, the landscape divides into diagnostic platforms that support clinical decision making and pulmonary delivery systems that enable therapeutic deposition. Within pulmonary delivery, submodalities include dry powder inhalers, inhalers, and nebulizers, and each submodality carries distinct trade-offs in dose consistency, maintenance burden, and usability for patients with variable pulmonary function. Inhaler formats further bifurcate into metered dose inhalers and soft mist inhalers, with metered dose options offering compactness and legacy familiarity while soft mist approaches provide gentler aerosol generation that can benefit certain patient cohorts. Nebulizer technology also spans multiple architectures; jet nebulizers remain widely used due to established clinical familiarity, mesh nebulizers present advantages in portability and efficiency, and ultrasonic nebulizers deliver high output useful in specific therapeutic contexts.

Distribution channel segmentation reveals differentiated adoption pathways and service expectations across hospital pharmacies, online pharmacies, retail pharmacies, and specialty centers. Each channel introduces unique requirements for packaging, patient education, returns management, and contract terms, which in turn affect lifecycle support and adherence programs. End user segmentation-clinics, home care, and hospitals-further shapes device requirements. Devices intended for home care must prioritize ease of use, durability, and remote monitoring capabilities, whereas hospital and clinic deployments emphasize sterilization, workflow integration, and interoperability with electronic medical records.

Modality distinctions between invasive and non-invasive approaches create separate regulatory and operational considerations. Invasive devices demand more rigorous sterile manufacturing and procedural training, whereas non-invasive technologies must excel in ergonomics and patient adherence to be effective in a home setting. Component-level segmentation highlights pumps, sensors, and valves as critical subsystems; pumps can be delivered as peristaltic designs or syringe-based mechanisms depending on dosing precision needs, while sensors commonly include flow sensors and pressure sensors that inform both clinician decision making and closed-loop control strategies. Finally, patient-type segmentation into adult and pediatric cohorts drives divergent human factors requirements, device sizing, and dosing regimens. Collectively, these segmentation lenses create a mosaic of product and commercial imperatives that must be reconciled to deliver clinically meaningful and commercially viable offerings.

Regional dynamics and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory, commercial, and operational choices

Regional dynamics exert a major influence on regulatory pathways, reimbursement frameworks, and the practicalities of deploying cystic fibrosis devices. In the Americas, centers of clinical expertise and well-established specialty pharmacy networks support rapid adoption of novel delivery platforms, while payer scrutiny and procurement procedures require robust health-economic evidence and clear demonstrations of real-world outcomes. Cross-border manufacturing capacity and nearshoring initiatives in the Americas have become more prominent as companies respond to tariff shocks and aim to shorten lead times.

Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement environment characterized by varying national health technology assessment processes and procurement norms. In this region, centralized clinical data packages that address diverse regulatory expectations are especially valuable. Local partnerships with specialty centers and training programs can accelerate clinician acceptance, particularly where hospital-based infusion and nebulization services remain concentrated. Meanwhile, capacity building in some Middle Eastern and African markets requires targeted support for cold chain logistics, clinician training, and patient education to enable home-based therapy expansion.

Asia-Pacific encompasses a broad spectrum of maturity levels, from markets with advanced device uptake and domestic manufacturing capabilities to emerging markets where adoption is constrained by infrastructure and reimbursement gaps. In leading Asia-Pacific markets, agile regulatory systems and strong contract manufacturing ecosystems provide opportunities for scale and innovation. Conversely, in developing healthcare systems across the region, digital health and mobile-enabled care models can act as force multipliers, improving follow-up, adherence monitoring, and supply distribution for home-based management. Taken together, regional variation underscores the necessity of adaptive commercial strategies and regulatory intelligence that align product configurations with local clinical practice and health system incentives.

Strategic behaviors and capability investments that distinguish leading device companies and create durable competitive advantage in cystic fibrosis care

Leading companies in the cystic fibrosis device arena are coalescing around several strategic imperatives that differentiate winners from the rest of the field. First, firms prioritizing integrated solutions that couple precise pulmonary delivery with embedded sensing and connectivity are creating stickier value propositions, as clinicians and payers increasingly expect devices to generate actionable data that supports adherence and outcome monitoring. Second, manufacturers that embrace modular design and flexible manufacturing can respond more rapidly to component shortages, tariff changes, and local market requirements, giving them a resilience advantage in turbulent supply environments.

Partnerships and ecosystem plays have emerged as critical accelerants for both product development and market access. Collaborations between device developers, diagnostic providers, and digital health companies enable combined evidence generation strategies that tie device use to measurable clinical endpoints. Additionally, strategic alliances with specialty pharmacies and home-care providers expand distribution reach and patient support capabilities. Companies investing in robust post-market surveillance and real-world evidence programs are better positioned to negotiate reimbursement and demonstrate value over the product lifecycle.

Finally, talent and capability investments in regulatory affairs, health economics, and human-centered design are proving decisive. Organizations that combine clinical trial expertise with deep user-experience research are producing devices that meet regulatory expectations while simultaneously improving adoption among pediatric and adult patient populations. These cumulative capabilities define the competitive frontier and provide a template for companies seeking sustainable differentiation.

Actionable strategic priorities for device makers and healthcare leaders to ensure resilient sourcing, rapid adoption, and measurable clinical value in cystic fibrosis care

Industry leaders should adopt a set of targeted, actionable priorities to translate technological potential into sustained clinical and commercial success. First, design devices with modularity and component commonality to enable rapid vendor substitution and regional manufacturing shifts without compromising clinical performance. This approach reduces exposure to tariff-induced cost volatility and shortens time-to-replenish for suppliers and providers. Second, integrate sensing and connectivity features that produce clinically relevant metrics, and align those metrics with payer evidence needs so that reimbursement discussions are grounded in patient-centered outcomes rather than device features alone.

Third, develop differentiated distribution strategies tailored to the expectations of hospital pharmacies, online pharmacies, retail pharmacies, and specialty centers, investing in training programs and patient support services that enhance adherence and reduce device-related complications. Fourth, prioritize dual-product development tracks that address both adult and pediatric usability constraints, ensuring that human factors testing is embedded early in the design process. Fifth, cultivate partnerships with home-care organizations and specialty centers to validate workflows and co-create education materials that enable safe and effective home administration. Finally, strengthen regulatory and health-economic capabilities to expedite approvals and build compelling value narratives that resonate with payers and procurement teams. By acting on these recommendations, organizations can increase resilience, accelerate adoption, and align product innovation with the operational realities of modern cystic fibrosis care.

A rigorous mixed-methods research framework combining primary clinician and supply-chain interviews with systematic secondary review and validation to ensure practical, evidence-based insights

This research synthesis is grounded in a mixed-methods approach that triangulates primary qualitative insights with rigorous secondary analysis to create a comprehensive understanding of the cystic fibrosis device environment. Primary research included structured interviews with pulmonologists, respiratory therapists, procurement officers, specialty pharmacists, and device engineers to capture real-world user needs, procurement constraints, and technical trade-offs. These conversations were supplemented by site visits and observational studies in clinic and home-care settings to validate usability assumptions and capture workflow integration challenges.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and public filings to contextualize therapeutic trends and device safety considerations. Supply-chain mapping used import-export data and manufacturing intelligence to trace component sourcing pathways and identify critical nodes susceptible to disruption. Findings were validated through an iterative process involving expert advisory reviews and cross-stakeholder workshops to reconcile divergent perspectives and stress-test tactical recommendations.

Limitations of the methodology include potential sampling bias in primary interviews and the rapidly evolving nature of device regulation and tariff policy, which require ongoing monitoring. To mitigate these constraints, the study employed purposive sampling across geographies and stakeholder types and incorporated sensitivity analyses in supply-chain scenarios. The result is a robust, actionable evidence base designed to inform strategic decision making without relying on single-source assumptions.

Strategic conclusion emphasizing how modular design, connectivity, evidence generation, and adaptive commercial models will determine success in cystic fibrosis devices

In closing, the cystic fibrosis device landscape is at an inflection point where technical innovation intersects with changing care delivery models and evolving policy pressures. Devices that succeed will do more than deliver medication or measure physiology; they will embed themselves into care pathways as trusted enablers of adherence, monitoring, and clinical decision support. The combined pressures of tariff dynamics, regional regulatory diversity, and heightened payer expectations make agility, evidence generation, and patient-centric design the pillars of sustainable strategy.

Stakeholders who focus on modularity, connectivity, and strong ecosystem partnerships can both mitigate near-term operational risks and capture longer-term opportunities to improve outcomes across adult and pediatric populations. Ultimately, a pragmatic blend of engineering excellence, clinical validation, and adaptable commercial models will determine which innovations translate into meaningful improvements in patient care. This synthesis provides a strategic foundation for leaders seeking to navigate the path ahead and convert insight into impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of smart nebulizer technologies with real time usage tracking and patient adherence analytics
  • 5.2. Development of portable high frequency chest wall oscillation devices for enhanced home airway clearance therapy
  • 5.3. Collaboration between device manufacturers and gene therapy developers to integrate targeted CFTR delivery systems
  • 5.4. Advances in dry powder inhaler formulations coupled with novel spacer designs to optimize CFTR modulator deposition
  • 5.5. Emergence of telemedicine enabled respiratory physiotherapy platforms with integrated wearable cough monitoring sensors
  • 5.6. Implementation of patient centric design enhancements focused on reducing treatment time and improving user comfort
  • 5.7. Regulatory harmonization and reimbursement strategies accelerating market access for innovative CF inhalation devices

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cystic Fibrosis Devices Market, by Product Type

  • 8.1. Diagnostic
  • 8.2. Pulmonary Delivery
    • 8.2.1. Dry Powder Inhalers
    • 8.2.2. Inhalers
      • 8.2.2.1. Metered Dose Inhalers
      • 8.2.2.2. Soft Mist Inhalers
    • 8.2.3. Nebulizers
      • 8.2.3.1. Jet Nebulizers
      • 8.2.3.2. Mesh Nebulizers
      • 8.2.3.3. Ultrasonic Nebulizers

9. Cystic Fibrosis Devices Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies
  • 9.4. Specialty Centers

10. Cystic Fibrosis Devices Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care
  • 10.3. Hospital

11. Cystic Fibrosis Devices Market, by Modality

  • 11.1. Invasive
  • 11.2. Non Invasive

12. Cystic Fibrosis Devices Market, by Component

  • 12.1. Pumps
    • 12.1.1. Peristaltic Pumps
    • 12.1.2. Syringe Pumps
  • 12.2. Sensors
    • 12.2.1. Flow Sensors
    • 12.2.2. Pressure Sensors
  • 12.3. Valves

13. Cystic Fibrosis Devices Market, by Patient Type

  • 13.1. Adult
  • 13.2. Pediatric

14. Cystic Fibrosis Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cystic Fibrosis Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cystic Fibrosis Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Koninklijke Philips N.V.
    • 17.3.2. Baxter International Inc.
    • 17.3.3. Drive DeVilbiss Healthcare, Inc.
    • 17.3.4. PARI GmbH
    • 17.3.5. Vyaire Medical, Inc.
    • 17.3.6. Smiths Group plc
    • 17.3.7. Teleflex Incorporated
    • 17.3.8. Omron Corporation
    • 17.3.9. ResMed Inc.
    • 17.3.10. Fisher & Paykel Healthcare Corporation Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CYSTIC FIBROSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CYSTIC FIBROSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CYSTIC FIBROSIS DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2025-2